(American Society for Microbiology 6 September 2014) An analysis of phase 2 and phase 3 clinical trials shows that a single injected dose of the neuraminidase inhibitor peramivir is safe and effective at alleviating influenza symptoms, including fever and viral shedding, when administered within 48 hours of the onset of symptoms.
Search the blog
SubscribeClick here to subscribe and receive new content by email.
View new books (QH staff only)
- Science for a better society and a stronger economy smh.com.au/comment/smh-ed… via @smh 3 hours ago
- Body washes up on South Stradbroke Island brisbanetimes.com.au/queensland/bod… via @brisbanetimes 3 hours ago
- Possum faeces may cause flesh-eating ulcers in humans abc.net.au/news/2014-09-1… via @ABCNews 4 days ago
- Qld Health Chikungunya management plan health.qld.gov.au/cdcg/documents… 4 days ago
- E-cigarettes to fall under Qld tobacco laws abc.net.au/news/2014-09-0… via @ABCNews 5 days ago
Tags usedAir pollution and analysis Biological and chemical weapons Clinical forensic medicine Clinical pathology Drug analysis and toxicology Environmental toxicology Food science Forensic DNA Forensic pathology Heavy metals / trace elements Hendra virus Influenza Leadership / Management Microbiology Physical evidence Radiation / Health physics Research Science - General Traffic medicine Vector borne diseases Virology Water analysis - biological contamination Water analysis - Non-biological contamination zJournal articles